Healthcare / Drug Manufacturers - Specialty & GenericKSE
$1433.00
-52.00 (-3.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-22.8B · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$134.9B
P/E
11.7x
↓EV/EBITDA
9.9x
↓ROE
9.5%
↑Gross Margin
30.3%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.8%
FCF CAGR
—
FCF margin
-49.5%
FCF / Net income
-1.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $46.07B · net income $11.55B · FCF $-22.81B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $46.07B | $46.07B | $44.29B | $51.96B | $51.83B |
| Net Income | $11.55B | $11.55B | $-14.09B | $-24.81B | $-25.09B |
| EBITDA | $14.18B | $14.18B | $-11.74B | $-21.69B | $-21.97B |
| EPS | 123.00 | 123.00 | -156.00 | -333.83 | -337.44 |
| Gross Margin | 30.3% | 30.3% | 44.6% | 44.2% | 47.5% |
| Operating Margin | -39.2% | -39.2% | -33.5% | -34.7% | -26.9% |
| Net Margin | 25.1% | 25.1% | -31.8% | -47.8% | -48.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.05 | 0.01 | 0.02 |
| Cash Flow | |||||
| Free Cash Flow | $-22.81B | $-22.81B | $-17.68B | $-40.44B | $-4.95B |
| Returns | |||||
| ROE | 9.5% | 9.5% | -13.3% | -32.0% | -24.5% |
| Valuation | |||||
| P/E | 11.65 | 11.65 | — | — | — |
| EV/EBITDA | 9.95 | 9.95 | — | — | — |
| P/B | 1.11 | 1.11 | 1.33 | 2.11 | 1.76 |
| Growth & Yield | |||||
| Revenue Growth | 4.0% | 4.0% | -14.7% | 0.2% | — |
| EPS Growth | 178.8% | 178.8% | 53.3% | 1.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.1%
EPS terminal req.
$127.15
Spread vs growth
177.7%
5Y implied EPS CAGR
4.6%
EPS terminal req.
$153.86
Spread vs growth
174.3%
10Y implied EPS CAGR
7.3%
EPS terminal req.
$247.79
Spread vs growth
171.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-156.00 → 123.00
Residual
-1.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.